Aerocrine

Aerocrine is a Swedish medical technology company founded in 1997, focusing on respiratory diagnostics, particularly for asthma management. The company was established by researchers from Karolinska Institutet who identified the importance of exhaled nitric oxide (FeNO) as a biomarker for asthma. Aerocrine developed the NIOX® test device, the first of its kind, which is used worldwide to monitor asthma symptoms and inform treatment decisions. The flagship product, NIOX VERO®, is a portable device that measures FeNO levels in exhaled breath, helping clinicians diagnose asthma and monitor treatment effectiveness. Aerocrine also offers diagnostic instruments and services designed to enhance asthma care. Their technology provides healthcare providers, including pulmonologists and allergists, with objective data on airway inflammation, facilitating personalized treatment plans for asthma patients. In 2015, Aerocrine was acquired by Circassia Pharmaceuticals, highlighting its significant role in the respiratory diagnostics market. The company continues to contribute to advancements in respiratory medicine and diagnostics.

• Employees 29
• Founded 1997